Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2022

View Archived Issues

ADAM10 may be a promising therapeutic target for AML

Sunshine Lake Pharma patents new GCGR and/or GLP-1 receptor agonists

Eubulus Biotherapeutics discloses new GPX4 inhibitors

Roche presents new EGFR mutant inhibitors

Reistone Biopharma divulges new CatC inhibitors

Palacky University patents new terpenoid derivatives

Novel mouse models of BrafV600E-driven thyroid tumors

Alaunos and NCI extend CRADA to assess use of Sleeping Beauty technology for TCR T-cell therapy

Ascentage receives IND clearance for first-in-human study of EED inhibitor APG-5918

HNSCC treatment should focus on targeting TSPAN1

Generian and Mitobridge collaborate to discover and develop small molecules for undruggable targets

Tumors might be nudged to more treatable state

IAMA reports responses with selective NKCC1 inhibitors in animal models of Down syndrome and autism

Anti-VISTA monoclonal antibody KVA-12.1 produces antitumor responses in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...